摘要
目的 分析辽宁中医药大学附属医院肿瘤科殷东风教授临床应用含活血化瘀药复方治疗恶性肿瘤伴高凝状态的用药规律及安全性。方法 采用回顾性研究方法,分析复方中活血化瘀类药伍用情况、使用频次与中医四诊的关系,患者处方中活血化瘀药的剂量与体力状态(ZPS,5分法)的关系及不良事件发生情况;统计未化疗患者用药前后肝肾功能、血常规及凝血的变化。结果 殷东风在辨证论治的原则下遵循药物兼顾的病因病机或症状的数目多少、症状的普遍性及药物的对症性的用药规律,治疗50例恶性肿瘤伴高凝状态患者。活血化瘀类药的应用剂量在10~15 g,剂量与PS评分的关系,从最大值、最小值和中位数看差异无统计学意义(P> 0.05),PS评分与其不相关;50例恶性肿瘤伴高凝状态患者不良事件发生率为8%,无明显出血不良反应;30例未化疗患者用药后无明显肝肾功能、血常规的异常变化(P> 0.05),凝血功能中的纤维蛋白原(FBG)水平变化差异有统计学意义(P <0.05)。结论 在合理的用量及配伍前提下,含活血化瘀药复方治疗恶性肿瘤伴高凝状态安全性好,无明显不良反应,并能改善患者的血液高凝状态。
Objective To analyze the medication regularity and safety of Professor Yin Dongfeng from the Cancer Department of the Affiliated Hospital of Liaoning University of traditional Chinese medicine in the clinical application of compound drugs containing blood activating and stasis removing drugs in the treatment of malignant tumors with hypercoagulability.Methods A retrospective study was used to analyze the relationship between the use of blood activating and blood stasis removing drugs,the frequency of use and the four diagnostic methods of traditional Chinese medicine,the dose of blood activating and blood stasis removing drugs in patients'prescriptions,their physical strength(ZPS,5-point method)and the occurrence of adverse events;The changes of liver and kidney function,blood routine test and blood coagulation in patients without chemotherapy before and after treatment were counted.Results Yin Dongfeng used the principle of dialectical treatment,treated 50 patients with malignant tumor with hypercoagulable state by following the principle of giving consideration to the number of etiology,pathogenesis or symptoms,the universality of symptoms and the rule of symptomatic medication.The dosage of drugs for activating blood circulation and removing blood stasis was 10~15 g,and the relationship between the dosage and PS score was no difference from the maximum,minimum values and the median values,the PS scores were not associated with them;The incidence of adverse events in 50 patients with malignant tumor and hypercoagulable state was 8%,and there was no obvious bleeding side effect;30 patients without chemotherapy had no significant abnormal changes in liver and kidney function and blood routine test(P>0.05),but the changes in fibrinogen(FBG)in coagulation function were statistically different(P<0.05).Conclusion On the premise of reasonable dosage and compatibility,the compound containing blood activating and stasis removing drugs is safe in treating malignant tumors with hypercoagulability,without obvious side effe
作者
马海刚
高宏
王晓东
MA Hai-gang;GAO Hong;WANG Xiao-dong(Ma Haigang,Liaoning University of traditional Chinese medicine,Shenyang 110032,China)
出处
《中国处方药》
2023年第10期138-141,共4页
Journal of China Prescription Drug
关键词
恶性肿瘤
高凝状态
活血化瘀药
用药规律
安全性
Malignant tumor
Hypercoagulable state
Blood activating and stasis removing drugs
Medication Rule
Safety
